Stocktoria
Q/C TECHNOLOGIES, INC. QCLS
Q/C TECHNOLOGIES, INC. (QCLS) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -4.08 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.268 |
| Retained earnings / assets | -3.501 |
| EBIT / assets | -0.239 |
| Equity / liabilities | 1.323 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| QCLS | Q/C TECHNOLOGIES, INC. | 3/9 | -9.87 | — | — |
| IDXX | IDEXX LABORATORIES INC /DE | 8/9 | 10.43 | 41.1 | +10.4% |
| QDEL | QuidelOrtho Corp | 5/9 | -0.56 | — | -1.9% |
| LNTH | Lantheus Holdings, Inc. | 4/9 | 4.61 | 30.6 | +0.5% |
| NEOG | NEOGEN CORP | 4/9 | -0.23 | — | -2.7% |
| MYGN | MYRIAD GENETICS INC | 5/9 | -5.88 | — | -1.6% |
| NTLA | Intellia Therapeutics, Inc. | 2/9 | -6.12 | — | +16.9% |
About Q/C TECHNOLOGIES, INC.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, and inflammatory bowel disease. It also develops Supera-CBD, a synthetic analog derivative of cannabidiol (CBD) to treat various conditions, including epilepsy, pain and anxiety/depression. In addition, it is involved in the development and eventual application of quantum computing technology, both for cryptocurrency applications;. The company was formerly known as TNF Pharmaceuticals, Inc. and changed its name to Q/C Technologies, Inc. in September 2025. The company was founded in 2014 and is headquartered in New York, New York.
FAQ
Is QCLS financially healthy?
Q/C TECHNOLOGIES, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does QCLS pay a dividend?
No, Q/C TECHNOLOGIES, INC. does not currently pay a dividend.
How profitable is QCLS?
In FY2025, Q/C TECHNOLOGIES, INC. had a return on equity of -53.5%.
Is QCLS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Q/C TECHNOLOGIES, INC.: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.